Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation (ATG FRES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00934557|
Recruitment Status : Unknown
Verified July 2009 by IRCCS Policlinico S. Matteo.
Recruitment status was: Recruiting
First Posted : July 8, 2009
Last Update Posted : July 8, 2009
Paediatric patients affected by haematological malignancies and eligible to undergo HSCT from an unrelated volunteer will be stratified according to the degree of compatibility with their donor, the source of haematopoietic stem cells employed (BM vs. PB) and the disease phase (good vs. poor prognosis). In particular, on the basis of compatibility with their donor, patients will be allocated to 2 different arms: those transplanted from an unrelated donor either perfectly matched or with a single allelic disparity at one of the HLA loci (i.e. A, B, C, and DrB1) vs. those transplanted from an unrelated donor either with 2 allelic disparities or with an antigenic disparity at the HLA loci (i.e. A, B, C, and DrB1).
Patients enrolled in the study will be randomized to receive ATG (Fresenius) at a dosage of either 30 mg/Kg (10 mg/Kg on days -4, -3 and -2) or 15 mg/Kg (5 mg/Kg on days -4, -3 and -2).
Good prognosis patients are defined as follows: ALL in 1st CR; ALL in 2nd CR belonging to S2 group; AML in 1st CR, AML in 2nd CR and relapsed more than 6 months after stopping therapy; NHL in 2nd CR; Ph+ CML in 1st CP; refractory cytopenia.
Poor prognosis patients are defined as follows: ALL in 2nd CR belonging to the S3-S4 group; ALL in ≥ 3rd CR; AML in 2nd CR and relapsed less than 6 months after stop therapy; secondary AML; NHL in 3rd CR; Ph+ CML in 2nd CP, as well as in AP; RAEB, RAEB-t, JMML.
|Condition or disease||Intervention/treatment||Phase|
|Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer||Drug: ATG Fresenius||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||42 participants|
|Masking:||None (Open Label)|
|Official Title:||Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation|
|Study Start Date :||March 2008|
|Experimental: Good prognosis/mismatched donor/BM||Drug: ATG Fresenius|
|Experimental: Good prognosis/mismatched donor/PB||Drug: ATG Fresenius|
|Experimental: Poor prognosis/matched donor/BM||Drug: ATG Fresenius|
|Experimental: Poor prognosis/matched donor/PB||Drug: ATG Fresenius|
|Experimental: Poor prognosis/mismatched donor/BM||Drug: ATG Fresenius|
|Experimental: Poor prognosis/mismatched donor/PB||Drug: ATG Fresenius|
|Experimental: Good prognosis/matched donor/BM||Drug: ATG Fresenius|
|Experimental: Good prognosis/matched donor/PB||Drug: ATG Fresenius|
- incidence and severity of acute GVHD [ Time Frame: 12 months ]
- • incidence of chronic GVHD •relapse rate •TRM •EFS •incidence of infection [ Time Frame: 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00934557
|Contact: Franco Locatelli, Professoremail@example.com|
|Pavia, Italy, 27100|
|Contact: Franco Locatelli, Professor +390382502607 firstname.lastname@example.org|
|Sub-Investigator: Maria Ester Bernardo, MD|
|Sub-Investigator: Marco Zecca, MD|